Overview

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension
Phase:
Phase 2
Details
Lead Sponsor:
Mineralys Therapeutics Inc.